Symbiotec

Indore, India Founded: 2002 • Age: 24 yrs Acquired By Rosewood Private Intvestments
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
Request Access

About Symbiotec

Symbiotec is a company based in Indore (India) founded in 2002 was acquired by Rosewood Private Intvestments in December 2018.. Symbiotec has raised $61.01 million across 4 funding rounds from investors including Actis, Franklin Templeton and British International Investment. The company has 1,822 employees as of May 31, 2025. Symbiotec offers products and services including Cortico-Steroid API, Steroid-Hormone API, and Intermediates. Symbiotec operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Jubilant Pharma and SeQuent, among others.

  • Headquarter Indore, India
  • Employees 1822 as on 31 May, 2025
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Symbiotec Pharmalab
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $87.38 M (USD)
    26
    as on Mar 31, 2024
  • Net Profit
    $12.25 M (USD)
    313
    as on Mar 31, 2024
  • EBITDA
    $21.55 M (USD)
    137
    as on Mar 31, 2024
  • Total Equity Funding
    $61.01 M (USD)

    in 4 rounds

  • Latest Funding Round
    $48 M (USD), Series C

    Oct 13, 2013

  • Investors
    Actis

    & 8 more

  • Employee Count
    1822

    as on May 31, 2025

  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Symbiotec

Symbiotec offers a comprehensive portfolio of products and services, including Cortico-Steroid API, Steroid-Hormone API, and Intermediates. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Active ingredients for corticosteroids in therapies like pain management

APIs for steroid hormones used in dermatology and pediatrics

Raw materials for API synthesis in pharmaceutical applications

People of Symbiotec
Headcount 50-200
Employee Profiles 17
Employee Profiles
People
Sukhman Kundi
Regulatory Affairs Officer
People
Nikhil Maru
General Manager
People
Anand Patel
Manager
People
Anil Satwani
Managing Director

Unlock access to complete

Funding Insights of Symbiotec

Symbiotec has successfully raised a total of $61.01M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series C — $48.0M
  • First Round

    (06 Aug 2007)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2013 Amount Series C - Symbiotec Valuation Actis
Mar, 2013 Amount Angel Round - Symbiotec Valuation R S Shapeti
Sep, 2011 Amount Series A - Symbiotec Valuation Franklin Templeton Investments
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Symbiotec

Symbiotec has secured backing from 9 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Actis, Franklin Templeton and British International Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Sustainable infrastructure projects are invested in for essential services.
Founded Year Domain Location
Government agency focused on small and medium-sized businesses
Founded Year Domain Location
Investments in multiple sectors are managed by Soyumm Marketing.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Symbiotec

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Symbiotec

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Symbiotec Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Symbiotec

Symbiotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Jubilant Pharma and SeQuent, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical and biotechnology company
domain founded_year HQ Location
Contract development, manufacturing, and analytical services for APIs are offered.
domain founded_year HQ Location
APIs and drug products are developed and valorized in pharmaceuticals.
domain founded_year HQ Location
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
domain founded_year HQ Location
APIs are developed and manufactured for therapeutic areas.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Symbiotec

Frequently Asked Questions about Symbiotec

When was Symbiotec founded?

Symbiotec was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Where is Symbiotec located?

Symbiotec is headquartered in Indore, India. It is registered at Indore, Madhya Pradesh, India.

Is Symbiotec a funded company?

Symbiotec is a funded company, having raised a total of $61.01M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9.22M, raised on Aug 06, 2007.

How many employees does Symbiotec have?

As of May 31, 2025, the latest employee count at Symbiotec is 1,822.

What is the annual revenue of Symbiotec?

Annual revenue of Symbiotec is $87.38M as on Mar 31, 2024.

What does Symbiotec do?

Symbiotec was established in 2002 in Indore, India, as a manufacturer in the pharmaceutical sector. Non-sterile APIs and intermediates derived from steroid hormones are produced, targeting therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, pediatrics, anti-infectives, and dermatology. Regulatory-compliant solutions are offered, alongside operations in research and quality control laboratories.

Who are the top competitors of Symbiotec?

Symbiotec's top competitors include Laurus Labs, Sterling Pharma Solutions and Provepharm Life Solutions.

What products or services does Symbiotec offer?

Symbiotec offers Cortico-Steroid API, Steroid-Hormone API, and Intermediates.

Who are Symbiotec's investors?

Symbiotec has 9 investors. Key investors include Actis, Franklin Templeton, British International Investment, R S Shapeti, and Rakesh Jhunjhunwala.

What is Symbiotec's valuation?

The valuation of Symbiotec is $32.19M as of Mar 2013.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available